Welcome to SDEE

Welcome to San Diego Entrepreneurs Exchange! 

The San Diego Entrepreneurs Exchange (SDEE) is a nonprofit 501(c)(3) organization run by local entrepreneurs for entrepreneurs and pre-entrepreneurs interested in Life Sciences, Biotech, Pharma, Medical Devices, Tech and Alternative Energy. SDEE was founded to provide a voice and resources for early stage startups, to encourage new entrepreneurs, and sponsor networking and educational services to help develop skills necessary to bring new businesses and funding to the San Diego area. 

SDEE Businesses Directory


SDEE PLATINUM SPONSOR

Alexandria Morrison Foerster

Struthers Family
Trust

SDEE GOLD SPONSORS

BioMed Realty

Ted Jacobs
Executive Managing Director
Global Life Sciences Practices Group

SDEE SILVER SPONSORS

Takeda San Diego

SDEE BRONZE SPONSORS

Duane Morris MaxCyte Wagenknecht Law Group Bronze Sponsor Marsh & McLennan



  • Tuesday, November 12, 2019 at 05:00 PM

    Bootcamp

    Thursday, November 21, 2019 at 05:30 PM · 40 rsvps
    New English Brewing Company in San Diego, CA

    November Happy Hour

    Come network with your fellow San Diego entrepreneurs at Happy Hour held at the New English Brewing Company in Sorrento Valley. This month's Happy Hour is sponsored by SDEE member, Axiom Real-Time Metrics. Axiom Real-Time Metrics delivers intuitive, powerful and cost-effective services and solutions focused on successful clinical trial execution and management. Axiom’s eClinical suite, Fusion, with 15+ optional modules, serves as a complete connected hub for clinical data and operational needs, enabling sponsors to tailor their solutions based on evolving study requirements. SDEE members, stop by the SDEE table first, make a name-tag, and then exchange your business card with Axiom for one free pizza ticket from Angry Pete's Pizza and one free drink ticket. (You must be an SDEE member to receive the free tickets.) Not a member yet? Just ask SDEE about the benefits of joining and/or ask members at the event about the benefits they've received from joining. Our members are happy to spread the word!  Everyone is welcome (registration is free!), SDEE members get 10% drinks discount.
    Tuesday, December 10, 2019 at 05:00 PM

    Year End Social

    Save the date! Get ready to mingle and jingle on Tuesday, December 10th! If you would like to embrace the holiday spirit and to donate a drawing item, please contact Danielle Hayes dhayes@sdentrepreneurs.org    Donors whose gift has a value of $100 or more will receive a special website and email mention.
    Tuesday, January 07, 2020 at 05:00 PM

    Bootcamp


  • Meet SDEE Community

    How Entrepreneurs are Innovating to Address Food Waste

    By Amy Duncan, Goldfish Consulting, Inc. Entrepreneurs like Elizabeth Murphy, Sarah Boltwala-Mesina, and Jonathan Zaidman are starting companies to help people who are concerned about sustainability easily minimize food waste. From plant-based catering, to composting, to food production—sustainability is a unifying theme. We heard about their efforts at “Food Waste Reimagined,” an event hosted by the SDEE Sustainability Group held on October 24 at WeWork UTC, sponsored by Morrison Foerster and Struthers Family Trust.
    read more

    SDEE Recognizes Volunteers with Karl Strauss Social Mixer

    On a warm fall evening, the many volunteers of SDEE got together for recognition of their efforts. Led by Kathrin Copley, chair of the SDEE volunteer committee, all of the committee chairs and their hard-working members were honored with appreciation and gratitude. Our numerous events and programs are orchestrated through our all-volunteer organization. It’s through the generous donation of their time that helps to improve our entrepreneurial community and support system. We have several committees that plan and host events, grow membership, attract corporate sponsors, and promote SDEE activities. We’re always welcoming new committee members. Volunteering with SDEE a great opportunity to contribute your knowledge, gain new experiences, and make a difference in the San Diego entrepreneurial scene. For more information, please email SDEE at info@sdentrepreneurs.org.  
    read more
    See all news

  • News From SDEE Members

    Erythropoietic Protoporphyria: A Rare Inherited Disorder

    In this post, I share a few thoughts about erythropoietic protoporphyria (EPP), a serious debilitating condition for which there are presently no approved treatments. EPP is a rare inherited disorder of heme biosynthesis characterized by dermal photosensitivity secondary to a partial deficiency of ferrochelatase. In a phenotypically similar X-linked protoporphyria (XLP), there is overactivity of the heme biosynthesis enzyme, erythropoietic aminolevulinate synthase (ALAS2). Both EPP and XLP result in the accumulation of the photosensitizer protoporphyrin IX (PPIX) in erythrocytes, plasma, skin and liver. The accumulated PPIX is activated by sun exposure, thus generating free radicals which damage tissue and cause severe pain. EPP is a devastating lifelong disorder with very few evidence-based clinical management tools and no approved treatments in the United States. The number of patients affected by EPP in the US is unknown. In Europe, it is estimated that about 1 in about 75,000 to 1 in 200,000 individuals are affected. Worldwide, EPP is the third most common porphyria, with an incidence of about 2 to 5 per 1,000,000 individuals. Diagnostic delay is not uncommon due to a lack of symptom awareness among pediatricians. Clinically, EPP is characterized by both cutaneous and extracutaneous manifestation. Phototoxicity usually begins in infancy and manifests as intolerance to sunlight, including tingling, stinging, burning, itching and pain having an onset within minutes of exposure to sun or UV light. The phototoxicity can also be accompanied by lichenification, loss of lunulae, edema, erythema and petechiae. A phototoxic reaction typically lasts from hours to a few days, although reactions lasting 10 or more days have been reported, often accompanied by social isolation, excruciating pain, anxiety and sleep impairment. Extracutaneous manifestations include PPIX-mediated bile duct obstruction, resulting in cholestatic liver injury in 20-30%, and eventually cholelithiasis, cholestatic hepatitis, fibrosis, cirrhosis and liver failure in 3-5% of patients. Progressive liver disease can require liver transplantation, although a replacement healthy liver can start the reaccumulating PPIX. Thus, liver transplantation is not curative without a sequential liver and hematopoietic stem cell or bone marrow transplantation to correct the underlying enzymatic defect. Photoprotection against UV-A and visible light, including sun avoidance are required to minimize cutaneous reactions and pain. Patients with EPP have to maintain a high level of vigilance about ambient and changing light conditions and undertake measures to minimize the risk of phototoxicity. Drastic lifestyle modification, including the use of protective clothing, skin foundation, shade, tinted windows and indoor living are essential to minimize the cutaneous sequelae of EPP. These symptoms, along with required behavioral modification markedly impact employment choices, socialization (sun avoidance), work and school attendance, productivity, activities of daily living and quality of life. One study reported that while most individuals with EPP were employed or attending school, almost half felt their choice of vocation had been influenced by their symptoms. Both lifestyle modification and sunlight avoidance can place a significant burden on families. Although a number of treatments, including high dose β-Carotene, Vitamin C, N-Acetyl Cysteine and narrow band UVB have been suggested, there is little evidence to support their use. The only evidence-based treatment for preventing phototoxicity in EPP is afamelanotide (Scenesse®), a controlled release subcutaneous implant (depot) from Clinuvel Pharmaceuticals, a Melbourne, Australia headquartered company. Afamelanotide, a structural analog of α-melanocyte stimulating hormone (α-MSH) was developed, patented and initially tested by Drs. Victor Hruby, Robert Dorr and (the late) Mac Hadley at the University of Arizona more than two decades ago. It was first envisaged as a sunless tanning agent. Afamelanotide is a melanocortin receptor agonist that binds predominantly to the melanocortin-1 receptor (MC1R), activating the synthesis of eumelanin which provides photoprotection through absorption of UV and visible light, scavenging of free radicals and increased superoxide dismutase availability. Scenesse was approved by the EMA in December 2014 for prevention of phototoxicity in adult patients with EPP as a 16 mg subcutaneous implant administered every two months. The UK marketing authorization for Scenesse is under “exceptional circumstances” for the prevention of phototoxicity in adult patients with EPP. Unfortunately, in 2017, the U.K. National Institute for Health and Care Excellence (NICE) concluded that Scenesse “is not recommended, within its marketing authorization, for preventing phototoxicity in adults with erythropoietic protoporphyria” and this ruling was upheld in 2018 on appeal. This means that the National Health Service (NHS) will not reimburse for Scenesse in England. In reaching its decision, NICE made several observations about the clinical trial design and data submitted by Clinuvel, including (i) inadvertant treatment allocation unmasking (unblinding); (ii) a "small" but statistically significant benefit in daylight exposure without pain (approximately 10 minutes per day); and (iii) the pharmaceutical sponsor's the choice, validation, and relevance for quality of life instruments. In June 2018, Clinuvel submitted an NDA for which FDA has granted a Priority Review and assigned a PDUFA date of July 8, 2019. In summary, there is a need for improved early diagnosis of EPP to reduce sun exposure and provide appropriate follow up, including monitoring for hepatic complications. This can be done through improved education and orphan diseases awareness. There is a need for improved treatments with robust efficacy in EPP, preferably by the oral route. There is also a need for improved study designs that leverage our increased understanding of adaptive clinical trials, quality of life and health economic outcomes, and possible integration of photoprovocation in clinical trials. Finally, it is important to appreciate the potential role of geographic and seasonal differences in natural sunlight duration and occuptaionala nd recreational time spent outdoors as potential variables in EPP clinical trials.  Dr. Najib Babul, PharmD, MBA
    read more

    Neuropore achieves $5 million (USD) milestone from UCB collaboration

    Neuropore announced advancement of UCB0599 to next phase.  UCB0599 is an orally bioavailable, brain barrier penetrant small molecule that prevents the oligomerization of alpha-synuclein. Alpha-synuclein oligomerization and aggregation is implicated in Parkinson’s disease and other degenerative diseases. By inhibiting misfolding and oligomerization of alpha-synuclein, it is believed that the progression of Parkinson’s disease can be slowed or halted. UCB0599 belongs to a series of molecules discovered by Neuropore, which were licensed to UCB in 2014 (Press Release)
    read more
    See all news or Share Your Own News

Attend SDEE Events Donate | Sponsor SDEE Become a Member

Connect with SDEE

Sign Up for SDEE Newsletter


SDEE PLATINUM SPONSORS

Morrison Foerster Alexandria

Struthers Family
Trust

SDEE GOLD SPONSORS

BioMed Realty

Ted Jacobs
Executive Managing Director
Global Life Sciences Practices Group

Brex logo

SDEE SILVER SPONSORS

Takeda San Diego Union Bank JP Morgan logo

SDEE BRONZE SPONSORS

Duane Morris MaxCyte Wagenknecht Barney and Barney Longfellow

SDEE is a nonprofit 501(c)(3) organization founded by local San Diego entrepreneurs
in order to provide a voice for the early stage start-up, to support new entrepreneurs and their companies,
and to sponsor networking and educational events
to help develop the skills necessary to bring funding, business, and jobs to the San Diego area.

© 2015 San Diego Entrepreneurs Exchange. All Rights Reserved